Analysts Set $10.00 Target Price for Kitov Pharmaceuticals Holdings Ltd (KTOV)
Kitov Pharmaceuticals Holdings Ltd (NASDAQ:KTOV) has received a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that cover the company, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy rating.
Brokerages have set a 1-year consensus price objective of $10.00 for the company, according to Zacks. Zacks has also assigned Kitov Pharmaceuticals an industry rank of 107 out of 265 based on the ratings given to related companies.
Separately, HC Wainwright upgraded shares of Kitov Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $10.00 price objective for the company in a research note on Tuesday, November 21st.
TRADEMARK VIOLATION NOTICE: This story was first posted by Watch List News and is the property of of Watch List News. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international trademark and copyright law. The legal version of this story can be accessed at https://www.watchlistnews.com/analysts-set-10-00-target-price-for-kitov-pharmaceuticals-holdings-ltd-ktov/1773272.html.
About Kitov Pharmaceuticals
Kitov Pharmaceuticals Holdings Ltd is an Israel-based company that develops non-steroidal anti-inflammatory drugs that treat pain without raising blood pressure, thus avoiding the increased risk of heart attacks, strokes or death.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kitov Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kitov Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.